CRINETICS PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders: Matthew K. Fust

CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Matthew K. Fust”): 67,615,092 for, 17,700,974 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 39,770,402 for, 5,804,857 withheld, 0 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

Description as filed by funds: To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders: R. Scott Struthers, Ph.D.

CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: R. Scott Struthers, Ph.D.”): 69,586,919 for, 15,729,147 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 40,447,665 for, 5,127,594 withheld, 0 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

Description as filed by funds: To elect three directors to serve as Class I directors for a three-year term to expire at the 2028 annual meeting of stockholders: Rogerio Vivaldi Coelho, M.D.

CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Rogério Vivaldi Coelho, M.D.”): 68,864,528 for, 16,451,538 withheld, per its Form 8-K filed June 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 39,828,513 for, 5,746,746 withheld, 0 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

Description as filed by funds: To consider and vote upon, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission;

CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“3. Approval, on an advisory basis, of the compensation of the Company's named executive officers”): 82,658,715 for, 2,636,436 against — passed, per its Form 8-K filed June 12, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three - Approval, on an advisory basis, of the compensation of the Company's named executive officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 73 managers: 44,924,666 for, 642,835 against, 7,758 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 196 managers: 62,002,357 for, 1,925,486 against, 2,324 abstained, 13,667 not voted, 505,019 mixed. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To consider and vote upon the ratification of the selection of BDO USA, P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2025;

CRINETICS PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of Selection of Independent Registered Accounting Firm”): 88,742,805 for, 129,064 against — passed, per its Form 8-K filed June 12, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two - Ratification of Selection of Independent Registered Accounting Firm The Company's stockholders ratified the selection of BDO USA, P.C. as the Company's independent registered accounting firm for the fiscal year ending December 31, 2025.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 45,566,865 for, 636 against, 7,758 abstained.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.